Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL5095328 | 0.98 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL20298871 | 0.98 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL27816908 | 0.98 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL25311486 | 0.96 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL29089144 | 0.96 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL377416 | 0.96 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL28001186 | 0.96 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL30528009 | 0.96 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL872998 | 0.96 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL27466658 | 0.96 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197315-A1 | ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER | ORIENT PHARMA CO., LTD. (TW) | 2020-06-25 | — | — | US | disclosed |
| US-20200101021-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS | DURECT CORPORATION (US) | 2020-04-02 | — | — | US | disclosed |
| US-20190231702-A1 | Oral Pharmaceutical Dosage Forms | DURECT CORP (US) | 2019-08-01 | — | — | US | disclosed |
| US-10300142-B2 | Compositions with a rheological modifier to reduce dissolution variability | DURECT CORPORATION (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3481381-A1 | ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER | Durect Corporation (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-109475505-A | Peroral dosage form with pharmaceutical compositions, barrier layer and medicine layer | 度瑞公司 | 2019-03-15 | — | — | CN | disclosed |
| US-10206883-B2 | Oral pharamaceutical dosage forms | DURECT CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180339049-A1 | COMPOSITIONS WITH A RHEOLOGICAL MODIFIER TO REDUCE DISSOLUTION VARIABILITY | PAIN THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| US-20180236078-A1 | Compositions with a Rheological Modifier to Reduce Dissolution Variability | DURECT CORP (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180193275-A1 | Oral Pharmaceutical Dosage Forms | DURECT CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-6183466-B1 | Dosage form comprising a capsule | ALZA CORPORATION | 2001-02-06 | — | — | US | disclosed |
| US-6096339-A | Dosage form, process of making and using same | ALZA CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| WO-2000038655-A1 | DOSAGE FORMS COMPRISING POROUS PARTICLES | ALZA CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000035419-A2 | CONVERSION OF LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS | ALZA CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| US-5413572-A | Osmotic dosage system for liquid drug delivery | ALZA CORPORATION (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0523172-B1 | OSMOTIC DOSAGE SYSTEM FOR LIQUID DRUG DELIVERY | ALZA CORP (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5324280-A | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug | ALZA CORPORATION (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0523172-A1 | OSMOTIC DOSAGE SYSTEM FOR LIQUID DRUG DELIVERY. | ALZA CORP (US) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991015196-A1 | OSMOTIC DOSAGE SYSTEM FOR LIQUID DRUG DELIVERY | ALZA CORPORATION (US) | 1991-10-17 | — | — | WO | disclosed |
| US-4627850-A | Osmotic capsule | ALZA CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |